These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 33895475)

  • 1. Potential SARS-CoV-2 vaccines: Concept, progress, and challenges.
    Hosseini SA; Zahedipour F; Mirzaei H; Kazemi Oskuee R
    Int Immunopharmacol; 2021 Aug; 97():107622. PubMed ID: 33895475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
    Lu L; Zhang H; Zhan M; Jiang J; Yin H; Dauphars DJ; Li SY; Li Y; He YW
    Sci China Life Sci; 2020 Dec; 63(12):1833-1849. PubMed ID: 33355886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 - Recent advancements in identifying novel vaccine candidates and current status of upcoming SARS-CoV-2 vaccines.
    Iqbal Yatoo M; Hamid Z; Parray OR; Wani AH; Ul Haq A; Saxena A; Patel SK; Pathak M; Tiwari R; Malik YS; Sah R; Rabaan AA; Rodriguez Morales AJ; Dhama K
    Hum Vaccin Immunother; 2020 Dec; 16(12):2891-2904. PubMed ID: 32703064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments.
    Canedo-Marroquín G; Saavedra F; Andrade CA; Berrios RV; Rodríguez-Guilarte L; Opazo MC; Riedel CA; Kalergis AM
    Front Immunol; 2020; 11():569760. PubMed ID: 33362758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 Vaccine: A comprehensive status report.
    Kaur SP; Gupta V
    Virus Res; 2020 Oct; 288():198114. PubMed ID: 32800805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies.
    Salimi-Jeda A; Abbassi S; Mousavizadeh A; Esghaie M; Bokharaei-Salim F; Jeddi F; Shafaati M; Abdoli A
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108232. PubMed ID: 34673335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fast-spreading COVID variant can elude immune responses.
    Callaway E
    Nature; 2021 Jan; 589(7843):500-501. PubMed ID: 33479534
    [No Abstract]   [Full Text] [Related]  

  • 10. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the road to ending the COVID-19 pandemic: Are we there yet?
    Case JB; Winkler ES; Errico JM; Diamond MS
    Virology; 2021 May; 557():70-85. PubMed ID: 33676349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies.
    Raman R; Patel KJ; Ranjan K
    Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 reinfection and implications for vaccine development.
    Nainu F; Abidin RS; Bahar MA; Frediansyah A; Emran TB; Rabaan AA; Dhama K; Harapan H
    Hum Vaccin Immunother; 2020 Dec; 16(12):3061-3073. PubMed ID: 33393854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
    Frederiksen LSF; Zhang Y; Foged C; Thakur A
    Front Immunol; 2020; 11():1817. PubMed ID: 32793245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2: Unique Challenges of the Virus and Vaccines.
    Mahmoodpoor A; Sanaie S; Samadi P; Yousefi M; Nader ND
    Immunol Invest; 2021 Oct; 50(7):802-809. PubMed ID: 34109900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review.
    Chauhan N; Soni S; Gupta A; Aslam M; Jain U
    J Med Virol; 2021 Apr; 93(4):1967-1982. PubMed ID: 33270225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 vaccines: what do we know so far?
    Dhillon P; Altmann D; Male V
    FEBS J; 2021 Sep; 288(17):4996-5009. PubMed ID: 34288409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates.
    Pillet S; Arunachalam PS; Andreani G; Golden N; Fontenot J; Aye PP; Röltgen K; Lehmicke G; Gobeil P; Dubé C; Trépanier S; Charland N; D'Aoust MA; Russell-Lodrigue K; Monjure C; Blair RV; Boyd SD; Bohm RP; Rappaport J; Villinger F; Landry N; Pulendran B; Ward BJ
    Cell Mol Immunol; 2022 Feb; 19(2):222-233. PubMed ID: 34983950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques.
    Rosati M; Agarwal M; Hu X; Devasundaram S; Stellas D; Chowdhury B; Bear J; Burns R; Donohue D; Pessaint L; Andersen H; Lewis MG; Terpos E; Dimopoulos MA; Wlodawer A; Mullins JI; Venzon DJ; Pavlakis GN; Felber BK
    PLoS Pathog; 2021 Sep; 17(9):e1009701. PubMed ID: 34551020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.